Comment on: Final results from the vedolizumab extended access program multinational study demonstrate long-term
Joaquín Borrás-Blasco1, Alejandro Valcuende-Rosique2, Silvia Cornejo-Uixeda3
1Pharmacy Department, Hospital de Sagunto, Avda Ramon y Cajal s/n Sagunto, Valencia 46520, Spain.
No abstract available in PubMed .
More Related Videos
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
